Project Name: Stem Cell Drug Screening Platform

Project Owner: Shandong Huasi Biotechnology Co., Ltd.

Project Profile: The evaluation of new drugs needs to go through four stages: laboratory study, animal experiment (clinical drug toxicological experiment), clinical trial study and new drug testing. This method of evaluation has the disadvantages of high cost, long period and low positive rate, etc. The company has signed a strategic cooperation agreement with the Institute of Genetic Regenerative Medicine of the Ukrainian National Academy of Medical Sciences to establish the China-Ukraine Stem Cell Research Center and develop a screening platform for stem cell drugs. The platform, which screens drugs from the human cell layer, has the advantages of low cost, short cycle, and little effect difference from laboratory research to animal experiment. It will subvert the traditional evaluation system in terms of new drug development, efficacy and toxicity evaluation to form a new evaluation system which will improve the screening rate of new drugs and reduce the cost of new drug R&D by 40%-50% compared with the traditional drug evaluation system.

Contact Person: Li Yuqiu

Email: huasisw@vip.163.com